Final results of CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma
   Google Scholar   
Citation:
Hematol Oncol vol 35 (suppl S2) 51
Meeting Instance:
ICML 2017
Year:
2017
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Primary
Analysis:
Long-Term-Followup
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
2762  
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882  
Corr. Author:
 
Authors:
                     
Networks:
CAPITAL, IL017, LAPS-MO011, LAPS-NC007, LAPS-OH007, NY018   
Study
CALGB-50803
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: